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Abstract 
Background. The leading cause of premature death in chronic kidney disease (CKD) is 
cardiovascular disease (CVD), but risk assessment in renal patients is still challenging. The aim 
of the study is to analyze factors predicting accelerated progression of common carotid intima-
media thickness (CCIMT) in a CKD cohort after two years of follow-up (2010-2012).  
Methods. The study included 1152 patients from the NEFRONA cohort with CKD stage 3 to 5D 
and without clinical history of previous CVD. CCIMT was measured at the far wall on both 
common carotids. CCIMT progression was defined as the change between CCIMT at baseline 
and CCIMT at 24 months for each side, averaged and normalized as change per year. Accelerated 
progressors were defined as those with a CCIMT change over the 75th percentile.  
Results. The median CCIMT progression rate was 0.0125 mm per year, without significant 
differences between CKD stages. The cut-off value for defining accelerated progression was 
0.0425 mm per year. After adjustment, age was a common factor among all CKD stages. 
Traditional cardiovascular risk factors like diabetes and systolic blood pressure were predictors of 
progression in CKD stages 4-5, whereas HDL and LDL cholesterols predicted progression in 
women in stage 3. Mineral metabolism factors predicting accelerated progression were serum 
phosphorus in stage 3 and 5D; low 25-hydroxyvitamin D and parathyroid hormone levels over 
110 pg/ml, in stage 4-5; and iPTH levels out of the recommended range in stage 5D.  
Conclusions. Mineral metabolism parameters might predict accelerated CCIMT progression 
from early CKD stages. 
Keywords: intima-media thickness, chronic kidney disease, atheromatosis progression, 
parathyroid hormone, phosphorus, vitamin D.  
 
 
 
 
 
 
 
  
 3 
INTRODUCTION  
Atheromatosis is a multifactorial inflammatory fibroproliferative process of the artery wall, with 
a high prevalence in chronic kidney disease (CKD) and one of the most common forces behind 
cardiovascular disease (CVD) [1,2]. Individuals with chronic kidney disease are at a higher risk 
of cardiovascular events than the general population [3], but risk assessment in this population is 
difficult due to the lack of accuracy of current algorithms [4]. Nonetheless, the use of non-
invasive vascular ultrasound imaging is an emerging tool with promising outcomes for 
cardiovascular risk assessment in CKD patients [5,6].  
Carotid intima-media thickness (IMT), defined as the distance between the intimal-luminal and 
the medial-adventitial interfaces of the artery wall, is a reliable surrogate marker with predictive 
value on cardiovascular events in the general [7] and CKD populations [6,8]. In early stages of 
atheromatosis, IMT increases before the development of the plaque and it has been shown that 
individuals in which IMT progresses faster would be at a higher risk for future events [9].  
CKD is a multifactorial complex disease where a wide range of metabolic alterations are involved. 
Besides traditional cardiovascular risk factors, specific renal factors can play an important role in 
the early onset of CVD, explaining the excess risk attributable to kidney disease [10]. One of the 
main complications secondary to CKD is the dysregulation of mineral metabolism parameters, 
namely CKD related mineral-bone disorders (MBD) [11]. Disorders in the secretion of 
parathyroid and vitamin D hormones, main regulators of calcium and phosphorus homeostasis, 
have an important effect on many organs and tissues, including the vessels [12]. These alterations 
have been associated with an increased risk of cardiovascular events in dialysis patients [13,14]. 
Nevertheless, CKD-MBD begin early in the course of CKD and little is known about its 
predictive value in subclinical atheromatosis progression [15]. Studies examining the relationship 
between CKD and IMT commonly focus on analyzing cardiovascular risk factors associated with 
an increased IMT in a cross-sectional nature [16,17], and there are scarce data about IMT 
progression in this specific population [9,15,18]. Identification of the specific factors that 
influence IMT progression in CKD could uncover new therapeutic strategies to decrease 
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cardiovascular morbidity and mortality. Therefore, the aim of the present study was to analyze 
the factors associated with an accelerated progression of the common carotid artery intima-media 
thickness (CCIMT) in 1152 patients with stage 3 to 5D CKD, after two years of follow-up. 
MATERIALS AND METHODS   
Study Population 
NEFRONA is an observational multicenter prospective CKD cohorts study designed to evaluate 
the subclinical atherosclerosis burden and the predictive value of biomarkers and surrogate 
measures on CVD. Its design and baseline characteristics have been previously described [19,20]. 
Briefly, between 2010 and 2012, the NEFRONA study enrolled 2.445 patients free from clinical 
CVD aged 18-76 and who were recruited from 81 spanish hospitals and dialysis clinics. From the 
original NEFRONA Study cohort of 2445 patients with CKD, 888 patients were excluded from 
the 24-month follow-up visit. Namely, patients who had stenotic carotid plaque or had ankle-
brachial index (ABI) <07 (n=118), had a cardiovascular event during the 2 year follow-up (n=97), 
received a renal transplant (n=371), died from non-cardiovascular causes (n=58) or second visit 
non-attendees (n=244) were excluded from the follow-up visit. Some patients who attended the 
24-month ultrasound visit were excluded because of missing CCIMT values (n=31), having a 
plaque located in common carotid artery (CCA) at baseline (n=154); or incomplete laboratory 
data (n=220). Finally a total of 1552 were included in the present study (figure 1). 
All participants were included after providing informed consent. The study was approved by each 
local hospital ethics committee. 
Carotid ultrasound 
High-resolution B-mode ultrasound was conducted using a standardized protocol, and following 
the recommendations of the Mannheim Consensus [21]. CCIMT was measured at the far wall of 
both common carotid arteries in plaque free segments, 1 cm proximal to the carotid bulb and 
taking into account the mean value of 150 measurements performed on a 10 mm segment. The 
presence of atheromatous plaques was defined as an IMT ≥ 1.5 mm protruding into the lumen. 
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Ultrasound explorations were carried out by the same itinerant team of 5 trained technicians. 
Images were analyzed in a blinded fashion by a single reader from the UDETMA (Unit for the 
Detection and Treatment of Atherothrombotic Diseases, Hospital Universitari Arnau de Vilanova, 
Lleida, Spain). For the examinations, a computer-supported image analysis system (Vivid BT09 
and the semi-automatic software EchoPAC Dimension, General Electric) was used. 
To assess the quality of the measurements a sample of 20 individuals was measured 3-5 times on 
different days, obtaining an intraclass correlation coefficient of 0.93.  
CCIMT progression was defined as the difference between CCIMT at baseline and CCIMT at 24 
months for each side, and then averaged and normalized as change per year. Based on the aim of 
the study, accelerated CCIMT progression was defined as an IMT change equal or above the 75th 
percentile.  
Clinical and Biochemical data 
At recruitment, the itinerant team reviewed the hospital medical records for each selected subject 
and collected demographic data, medical history of comorbidities and treatments. 
Anthropometrical data and vital signs were obtained by the itinerant team using standardized 
methods[22]. Biochemical parameters were obtained from a routine fasting blood test performed 
not further than 3 months apart (either before or after) from the vascular exploration. Furthermore, 
in dialysis patients, blood sample was obtained before the second session of the week. 
Special attention was paid to those parameters measured with different methods. Particularly, 
iPTH was corrected using an established conversion method [23]. High-sensitivity C-reactive 
protein (hsCRP) and 25-hydroxyvitamin D were both analyzed in a centralized laboratory; hsCRP 
was determined by immunoturbidimetric method (Roche/Hitachi modular analytics) and 25-
hydroxyvitamin D levels by Elisa (IDS, UK). 
iPTH concentrations were categorized according to KDOQI guidelines for each renal stage [24], 
comparing the extreme groups with the target levels. 
The MDRD4 equation was used to estimate GFR, defining three CKD stages; stage 3 GFR 60-30 
ml/min per 1.73 m2; stage 4-5 GFR<30 ml/min per 1.73 m2; or dialysis. 
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Statistical analysis  
All analyses were conducted stratified by CKD stages because many of the potential predictive 
factors and confounders show a high variation along the CKD spectrum (i.e. phosphate and PTH 
levels are relatively normal in early stages whereas in late stages those levels increase sharply. On 
the contrary vitamin D levels are relatively stable until they drop in dialysis patients). Descriptive 
analysis included absolute and relative frequencies for qualitative variables, compared by Pearson 
chi-square test; and mean and standard deviation or median and interquartile range for 
quantitative data, compared by Student’s T or Mann-Whitney tests depending on the normality of 
the distribution. Comparisons of more than two groups of data were performed using one-way 
Anova (with Bonferroni post-hoc analyses for multiple comparisons) for parametric data or 
Kruskal-Wallis for non-parametric data. 
Factors predicting accelerated CCIMT progression were estimated by fitting a multivariate 
logistic regression model for each CKD stage. In order to avoid the over-representation of non-
accelerated progressors, sampling weights were assigned to each group. 
Special attention was paid for nonlinear relationships, evaluated by linear spline models with 
different knots (i.e. body mass index on dialysis and iPTH in all stages). Highly skewed variables 
were log-transformed before inference testing in regressions models (i.e hsCRP and 25-
hydroxyvitamin D). Explanatory variables strongly correlated were also analyzed, remaining 
those that best fitted the model (i.e systolic blood pressure versus pulse pressure and low-density 
lipoprotein cholesterol (LDL) versus total cholesterol).  
All multivariate analyses were adjusted for available variables based on the existing 
cardiovascular risk literature and for specific CKD factors that may play a role on CCIMT 
progression, according CKD stage.  
Models for CKD stage 3 and stages 4-5 were adjusted for age, sex, smoking (current and former 
versus non-smokers), diabetes, body mass index, systolic blood pressure, LDL and HDL 
cholesterol, log-transformed high-sensitive C-reactive protein, total calcium, phosphorus, log-
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transformed 25-hydroxyvitamin D and ranges of iPTH concentrations (using as reference 
KDOQI-recommended target range). 
Model for CKD 5D was adjusted for age, sex, smoking (current and former versus non-smokers), 
diabetes, body mass index in tertiles (reference middle tertile), systolic blood pressure, LDL and 
HDL cholesterol, log-transformed high-sensitive C-reactive protein, albumin, total calcium, 
phosphorus, log-transformed 25-hydroxyvitamin D, ranges of iPTH concentrations (using as 
reference KDOQI-recommended target range) and time on dialysis (months). 
Specific multiplicative interaction effects between sex and explanatory variables were tested and 
included in the model only if statistically significant, according to Likelihood Ratio test. The 
calibration of the models was assessed using Hosmer-Lemeshow χ2 statistic test. Statistical 
significance was set at a p-value <0.05. All analyses were performed using the SPSS software 
(version 21).  
RESULTS 
Baseline characteristics according to CKD stage 
Demographic and clinical data are depicted in table 1. Age and body mass index decreased 
significantly in more advanced CKD stages. Furthermore, the percentage of men was higher in 
stage 3 and decreased in more advanced CKD stages.  
Traditional cardiovascular risk factors (diabetes, hypertension and dyslipidemia) were common in 
stage 3 and 4-5, and decreased significantly in stage 5D. Altered mineral metabolism parameters 
(hyperphosphatemia, hyperparathyroidism, hypovitaminosis D) were more evident in more 
advanced CKD stages. 
Two-Year Progression in CCIMT 
CCIMT at baseline was significantly higher in stage 3 than in stage 4-5 or stage 5D. The median 
CCIMT progression rate was 0.0125 mm per year. There was neither differences in median 
progression rate between different CKD stages (stage 3: 0.0138 mm, stage 4-5: 0.0100 mm, stage 
5D: 0.0225 mm) nor in the 75th percentile, used as the threshold to define accelerated progression 
(stage 3: 0.0425mm, stage 4-5: 0.0425mm, stage 5D: 0.0400mm). Figure 21 shows the mean 
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values of CCIMT at baseline and the median changes after follow-up, according to sex and CKD 
stage. Mean CCIMT at baseline was significantly higher in men in stage 3 and 4-5 CKD, whereas 
the yearly change of median CCIMT was greater among men in dialysis.  
Baseline characteristics according to group of progression and CKD stage 
The characteristics between groups of accelerated and non-accelerated progressors by CKD stage 
are given in Table 2. Across all CKD stages, accelerated progressors were on average 4 to 6 years 
older and had a higher prevalence of carotid plaque at bifurcation or internal carotid segments 
than non-accelerated progressors. In individuals in stage 3, no significant differences were found 
between groups in any other of the variables analyzed. In stage 4-5, accelerated progressors were 
more likely to be diabetics, had higher systolic blood pressure and lower serum 25-
hydroxyvitamin D levels than non-accelerated progressors. In stage 5D, accelerated progressors 
were more frequently men, with greater body mass index, higher serum phosphorus, and most of 
them were taking vitamin D treatments. 
Predictors of accelerated CCIMT progression 
Traditional Risk Factors 
After adjusting for potential confounders (table 3), age was independently associated with an 
accelerated progression across all CKD stages. 
Diabetes and systolic blood pressure were predictors of accelerated CCIMT progression, among 
individuals in stage 4-5 and male sex was also a predictor in CKD stage 5D. 
Interaction effects were found between low-density lipoprotein cholesterol (LDL), high-density 
lipoprotein cholesterol (HDL) and sex in stage 3. Among women, LDL was positively associated 
with accelerated progression, whereas HDL was inversely related to accelerated progression 
(supplementary data figure 1 and table 1). 
Non-Traditional Risk Factors 
Serum phosphorus was independently associated with accelerated CCIMT progression among 
individuals in stage 3 and stage 5D, and 25-hydroxyvitamin D was inversely associated with 
accelerated progression in stage 4-5. 
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Figure 3 2 shows a U-shape relationship between iPTH levels and accelerated progression across 
all CKD stages, reaching statistical significance in individuals with iPTH levels over 110 pg/ml 
in stage 4-5, and among those in stage 5D with the serum iPTH lower than 150 pg/ml or above 
300 pg/ml. 
The potential confounding effect of the treatment with erythropoietin or intravenous iron was 
tested and disregarded. 
DISCUSSION 
This longitudinal study shows for the first time a strong and independent relationship between 
serum phosphorus, 25-hydroxyvitamin D and iPTH levels with accelerated CCIMT progression 
in individuals with moderate to end-stage renal disease without previous cardiovascular disease.  
In our study, the CCIMT change cut-off value to define accelerated progression progressors 
(0.0425 mm/y) is clearly higher than the normal rate in general population (defined in several 
studies to be between 0.0018 and 0.006 depending on sex)[25–27]. Furthermore, a change of 
0.035mm/y has been defined to significantly increase the risk of future cardiovascular events[28]. 
The annual overall CCIMT change of 0.024 mm is in agreement with other studies in renal 
patients [9,18] and other high risk populations like type 2 diabetic patients[29]. We did not find 
differences in CCIMT progression between CKD stages, in contrast with a study conducted by 
Desbien et al [9] which found an effect of renal function on IMT progression. This discrepancy 
might be explained by the differences in the cohort, as the NEFRONA cohort is composed of 
younger individuals, without prior cardiovascular disease. When the median change of 
progression was stratified by sex, it was significantly higher in men than in women in dialysis 
patients. In further multivariate analysis, being male was an independent factor predicting an 
accelerated progression in dialysis. This fact could explain, at least in part, previous results 
showing an independent and significant effect of male sex on cardiovascular events in dialysis 
patients [30]. However, whether CCIMT progression can predict future events remains to be 
determined, as controversial results have been published [9,31]. 
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In the present study, age has been found to be one of the most consistent factors predicting 
CCIMT progression, as it has been already reported in numerous studies [9,18]. Thus, age 
remains as the only factor that predicts accelerated progression of IMT across all CKD stages.  
In the general population, IMT progression can also be partly explained by the presence of lipid 
disorders [32]. However, the relationship between serum cholesterol and CVD is more complex 
in patients with CKD, probably due to the cholesterol-lowering effect of systematic inflammation, 
which increases as GFR decreases [33]. Indeed, three large randomized clinical trials have failed 
to show a beneficial effect of lipid-lowering therapy in reducing mortality in dialysis patients 
despite significant reduction in LDL [34]. In our study, no effect of LDL or HDL cholesterol 
levels was found in stage 4-5 or in dialysis patients. Even so, in stage 3 higher levels of LDL and 
lower levels of HDL predicted accelerated atherosclerosis among women. Our findings are 
similar to previous studies in which dyslipidemia was associated with increased IMT values in 
the early stages of renal disease[17,35]. Furthermore, the differential effects of lipids on IMT 
depending on sex have been previously demonstrated[36].  
One of the most important results of this study is that specific parameters of mineral metabolism 
play a key role in the fast development of subclinical atheromatosis. We found that serum 
phosphorus contributes to the accelerated CCIMT progression in CKD stage 3 and in dialysis. It 
has been reported that phosphorus load, even in the absence of outright hyperphosphatemia, 
could be an important promoter of atheromatosis [16,37] and several studies have correlated 
serum phosphorus levels with increased cardiovascular risk in dialysis patients [13,38].  
It is noteworthy that we found an independent association between serum PTH and CCIMT 
accelerated progression. Although the tendency for a U-shaped curve for iPTH levels is present in 
all the stages, it only reached statistical significance in dialysis patients and in patients with levels 
over the recommended target in stage 4-5. The fact that K-DOQI proposed targets are not easily 
achieved is a common issue that has been previously reported [11]. It has also been documented 
that both, low and high serum iPTH increase the risk of mineral metabolism disturbances, soft 
tissue calcifications and cardiovascular mortality in dialysis patients [13,14]. Nonetheless few 
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stu[39,40]. Blondon et al. evaluated the associations of PTH and 25-hidroxyvitamin D with 
progression of carotid IMT after 9.4 years of follow-up in 3251subjects from the Multi-Ethnic 
Study of Atherosclerosis, and they found no evidence of an association between these hormones 
and progression [39]. Reis et al also failed in finding an association between PTH and carotid 
IMT in a community-based cohort study of 654 participants[40]. However, both studies were 
general population-based cohorts with much lower levels of PTH than the ones reached in our 
CKD population, and that may partly explain the discrepancies with our results. In fact Choi et al. 
found an association between PTH and carotid IMT among postmenopausal women[41] and a 
recent study based in a CKD cohort dies include iPTH concentrations when assessing IMT 
demonstrated a regression of IMT after renal transplantation, showing a risk reduction when 
parameters as iPTH and phosphorus were corrected [15]. The underlying mechanisms by which 
iPTH affects IMT progression are complex and multifactorial. Indeed, iPTH receptors have been 
found in endothelial cells [42], and smooth muscle cells [43]. Thus, on the one hand, a lower 
iPTH receptor activation in vascular smooth muscle cells could enhance IMT progression by a 
WNT-mediated pathway [44]. On the other hand, high iPTH levels could indirectly increase IMT 
by activating local production of active vitamin D, which has also been shown to increase 
proliferation of the medial layer [45]. In endothelial cells, iPTH may also have dual effects on 
IMT because it can increase nitric oxide production but also RAGE and IL6 [46]. 
Finally, the effect of vitamin D is also of interest. A role for low levels of 25-hidroxyvitamin D 
has been found only in stage 4-5. Although the bivariate analysis showed a similar difference in 
25-hidroxyvitamin D levels in dialysis patients, the significance of the effect disappeared in 
subsequent multivariate analysis. Nevertheless, the fact that vitamin D treatment was associated 
to CCIMT progression might hide the potential benefit of the effect of 25-hidroxyvitamin D. It 
has long been known that endothelial and vascular smooth muscle cells also express vitamin D 
receptors, and that its activation shows potential benefits in cardiovascular health [47]. Moreover, 
clinical studies have shown a strong association between vitamin D levels and cardiovascular 
mortality in renal patients [48]. In our study the absence of predictive value of serum 25-
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hidroxyvitamin D in stage 5D, may point to a possible lack of effects of native vitamin D 
supplementation in atherosclerosis progression in dialysis patients. 
Although the current study provides relevant data regarding the relationship between a wide 
range of potential risk factors for atheromatosis and IMT progression, the results should be 
interpreted within the context of an exploratory research about accelerated CCIMT progression, 
showing several limitations. Firstly, the short follow-up period presumes small changes in 
CCIMT and may have prevented us from obtaining associations among other meaningful factors 
studied. Nevertheless, the assessment of accelerated progression avoids in part this limitation, 
helping us to understand which factors predict a greater change in IMT. Secondly, the assessment 
of the CCA could lead us to find factors more related to this proximal area, historically associated 
with a higher shear stress. However, CCIMT represents a more accurate measurement than others 
segments of the vessel wall [21,49]. In addition, unmeasured confounding parameters such as 
fibroblast growth factor 23 levels impede us to make a comprehensive analysis of all the known 
factors affecting mineral metabolism. Finally, misclassification owed to measurement errors, 
which is susceptible to random errors and short-term variability, and residual confounding due to 
categorical transformations, might bias the results toward the null. 
Despite of these limitations the present study has several strengths. The NEFRONA cohort has an 
adequate sample size and centralization of analytical parameters and image readings. The absence 
of prevalent CVD together with an adjustment for a wide range of potential confounders, which 
are concomitant and often overlooked, may allow us to identify independent associations towards 
enhancing the current knowledge of the underlying mechanisms of atherogenesis in CKD. 
In summary, the present study demonstrates that independently of traditional cardiovascular risk 
factors, specifics factors related to CKD appear to be relevant, suggesting a potential role of 
serum phosphorus, vitamin D and iPTH concentrations in the accelerated subclinical 
atheromatosis process, which also begins in earlier stages of CKD.  
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FIGURE LEGENDS 
 
 
Figure 1. Flow chart of patient selection.  
 
Figure 2 1. Mean common intima-media thickness (CCIMT) at baseline and median change 
in CCIMT (mm/year) stratified by sex and CKD stage. Light gray bars indicate mean CCIMT 
at baseline in women. Dark gray bars indicate mean CCIMT at baseline in men. Dashed light 
gray line indicates median change in CCIMT among women. Dashed black line indicates median 
change in CCIMT among men. Error bars represent the standard error and the median absolute 
deviation, respectively. Mean CCIMT at baseline was increased in men compared with women in 
CKD 3 and CKD 4-5 (*:p< 0.05). Median change in CCIMT was increased in men compared 
with women in CKD 5D(*:p< 0.05). 
 
Figure 3 2. Frequencies and Odds Ratio of iPTH levels for accelerated CCIMT progression, 
by CKD stage. Bottom part of the figure shows percentage of accelerated progressors depending 
on iPTH levels distributed according to KDOQI guidelines (black bars). Top part of the figure 
shows the adjusted odds ratio (95% CI) for accelerated progression of CCIMT. CKD stage 3 and 
stages 4-5 were adjusted for age, sex, smoking (current and former versus non-smokers), diabetes, 
body mass index, systolic blood pressure, LDL and HDL cholesterol, log high-sensitive C-
reactive protein, total calcium, phosphorus, log 25-hydroxyvitamin D and ranges of iPTH 
concentrations (reference: KDOQI recommended target range). CKD 5D was adjusted for age, 
sex, smoking (current and former versus non-smokers), diabetes, body mass index in tertiles 
(reference: middle tertile), systolic blood pressure, LDL and HDL cholesterol, log high-sensitive 
C-reactive protein, albumin, total calcium, phosphorus, log 25-hydroxyvitamin D, ranges of iPTH 
concentrations (reference: KDOQI recommended target range), albumin and time on dialysis 
(months). 
 
 
 
 
 
 
 
 
 
 
 



